Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Ascidian Therapeutics and Forge Biologics Forge Partnership to Enhance RNA Editing Therapy for Stargardt Disease.
Jan 07, 2026
Contract Type
partnership
BostonBiotechnologyHealth CareMedicalTherapeutics
Description
Ascidian Therapeutics and Forge Biologics have announced a strategic partnership to advance the development and manufacturing of ACDN-01, focusing on innovative therapies for Stargardt disease. This collaboration includes comprehensive support from Forge, utilizing their advanced manufacturing technologies.
Company Information
Company
Ascidian Therapeutics
Location
Boston, Massachusetts, United States
About
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.